H-1B visa applicants face more disruptions amid social media checks and wage protection rules
The U.S. administration has lined up a slew of actions to restrict the use of H-1B visas by businesses.
Jim Cramer’s bullish on takeovers and acquisitions for 2026
CNBC’s Jim Cramer suggested dealmaking will help drive the market next year.
Greenland PM rebukes Trump special envoy overture
President Donald Trump on Sunday appointed Louisiana Governor Jeff Landry as a ‘special envoy’ to Greenland.
Shares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval
The FDA on Monday approved the first-ever GLP-1 pill from the Danish pharmaceutical giant.
Inside the rise of Gen Z’s nostalgia-fueled plush-toy craze as they delay adulthood
“The economy, the wars, everything is really depressing and serious, whereas toys just bring a little bit of joy back into life,” one toy director said.
Hanwha Ocean shares jump 10% after Trump says South Korean firm to build warships for U.S. Navy
Trump said that the frigates will be built at the Philadelphia shipyards, which Hanwha had invested $5 billion into.
Asia’s worst-performing currency is set for a rocky start to 2026
Rupee emerges as Asia’s worst performing currency in 2025 amid trade policy uncertainty and capital outflows.
‘No doubt’ U.S. economy is slowing, Invesco says, tipping Europe to outperform
Invesco’s Ben Gutteridge sees a mid-cycle slowdown in the U.S., with Europe poised to outperform in 2026.
Asia-Pacific markets mostly climb after AI trade lifts Wall Street overnight
Investors in Asia will watch out for AI-related plays in the region, as well as inflation reading out of Singapore.
FDA approves first GLP-1 pill for obesity from Novo Nordisk
The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own obesity pill.